Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, after market close. The company will hold a conference call and webcast to discuss the results and provide a business update on Friday, May 16, 2025, at 10:00 AM ET. Interested parties can access the conference call via U.S. toll-free number 1-877-877-1275 or international number 1-412-858-5202.
Biofrontera Inc. (NASDAQ:BFRI), un'azienda biofarmaceutica specializzata nella commercializzazione di prodotti dermatologici, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 15 maggio 2025, al termine delle contrattazioni di borsa. La società terrà una conference call e una trasmissione in webcast per discutere i risultati e fornire un aggiornamento aziendale il venerdì 16 maggio 2025 alle 10:00 ET. Gli interessati potranno partecipare alla conference call chiamando il numero verde statunitense 1-877-877-1275 o il numero internazionale 1-412-858-5202.
Biofrontera Inc. (NASDAQ:BFRI), una compañía biofarmacéutica enfocada en la comercialización de productos dermatológicos, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 15 de mayo de 2025, después del cierre del mercado. La empresa realizará una llamada de conferencia y una transmisión por webcast para discutir los resultados y ofrecer una actualización comercial el viernes 16 de mayo de 2025 a las 10:00 AM ET. Los interesados pueden acceder a la llamada a través del número gratuito en EE.UU. 1-877-877-1275 o el número internacional 1-412-858-5202.
Biofrontera Inc. (NASDAQ:BFRI)는 피부과 제품 상용화에 중점을 둔 바이오제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 15일 장 마감 후에 예정하고 있습니다. 회사는 2025년 5월 16일 금요일 오전 10시(동부시간)에 실적 논의 및 사업 현황 업데이트를 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 관심 있는 분들은 미국 무료 전화번호 1-877-877-1275 또는 국제 전화번호 1-412-858-5202를 통해 컨퍼런스 콜에 참여할 수 있습니다.
Biofrontera Inc. (NASDAQ:BFRI), une société biopharmaceutique spécialisée dans la commercialisation de produits dermatologiques, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 15 mai 2025, après la clôture des marchés. La société tiendra une conférence téléphonique et une webdiffusion pour discuter des résultats et fournir une mise à jour commerciale le vendredi 16 mai 2025 à 10h00 ET. Les personnes intéressées peuvent accéder à la conférence téléphonique via le numéro vert américain 1-877-877-1275 ou le numéro international 1-412-858-5202.
Biofrontera Inc. (NASDAQ:BFRI), ein biopharmazeutisches Unternehmen, das sich auf die Vermarktung dermatologischer Produkte spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 15. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate am Freitag, den 16. Mai 2025, um 10:00 Uhr ET zu geben. Interessierte können über die gebührenfreie US-Nummer 1-877-877-1275 oder die internationale Nummer 1-412-858-5202 an der Telefonkonferenz teilnehmen.
- None.
- None.
WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025. The results will be released after the market close on Thursday, May 15 and the company will host a conference call on Friday, May 16 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event: | Biofrontera Inc. First Quarter 2025 Financial Results and Business Update Conference Call |
Date: | Friday, May 16, 2025 |
Time: | 10:00am ET |
Conference Call: | 1-877-877-1275 (U.S.) |
Webcast: | Webcast | First Quarter 2025 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on ACCESS Newswire
FAQ
When will Biofrontera (BFRI) release Q1 2025 earnings?
What time is Biofrontera's (BFRI) Q1 2025 earnings call?
How can I join Biofrontera's (BFRI) Q1 2025 earnings call?
What does Biofrontera (BFRI) specialize in?
